| Nov 15 |
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
|
| Nov 12 |
Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...
|
| Nov 9 |
Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript
|
| Nov 7 |
Atea Pharmaceuticals files for $500M mixed securities shelf
|
| Nov 7 |
Atea Pharmaceuticals reports Q3 results
|
| Nov 7 |
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Oct 31 |
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
|
| Oct 30 |
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
|
| Oct 21 |
Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight
|
| Oct 16 |
ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
|
